Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $38.19, but opened at $35.45. Nanobiotix shares last traded at $36.53, with a volume of 5,813 shares changing hands.
Analyst Ratings Changes
NBTX has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Leerink Partners raised their price target on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Nanobiotix presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.33.
Get Our Latest Stock Analysis on NBTX
Nanobiotix Trading Down 5.5%
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Millennium Management LLC acquired a new stake in Nanobiotix in the 4th quarter valued at about $390,000. Marshall Wace LLP acquired a new position in shares of Nanobiotix in the 4th quarter worth approximately $220,000. Finally, Royal Bank of Canada grew its stake in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the last quarter. Institutional investors own 38.81% of the company’s stock.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.
Featured Stories
- Five stocks we like better than Nanobiotix
- 3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
- Gold.com’s Q4 Results Show Why This Stock Is More Than a Gold Bet
- Analog Devices Shows Why AI Is Not the Only Story Driving Chip Demand
- Cathie Wood Trimmed Palantir, But the Bigger Story Is Still Valuation
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
